Ann: RSH: Replacement Bidders Statement, page-6

Well ADR holders, I can’t really disagree with your scepticism.

I think Respiri need a good 12 months from here to prove themselves (to their own shareholders, as well as others) in terms of Australian-derived revenue and the upcoming expansion to the UK. The US CPT market beckons but it is some time away yet, and uptake for Wheezo in AU and UK needs to be seen before any plans to head to the States. Time will tell, some patience likely needed.

Now Adherium’s on my radar, I’ll follow along to see how your journey goes. All the best.

Cheers